LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR) today announced its plans for completing the next step towards initiating its Phase IIb clinical trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), planned to begin in the third quarter of 2007. As an important step toward this goal, CytRx plans to determine the maximum safe and well-tolerated dose of orally-administered arimoclomol. CytRx intends to proceed with this maximum dose in the Phase IIb efficacy trial for ALS, subject to U.S. Food and Drug Administration (FDA) approval.
